Biotech Values

[DewDiligence]

jbog’s point, such as it is, is that MNTA’s management is to blame for having the economics of the NVS-MNTA Lovenox collaboration depend heavily on the number of generics in the market. However, MNTA’s current management is, for the most part, not the same set of individuals as those who were around when MNTA inked the Lovenox collaboration with NVS in 2003.